GenAI and RWD in Pharma: 4 Questions to Fuel Effective Insights
Generative AI (GenAI) has become one of the most talked-about innovations in healthcare analytics, but for life sciences organizations, simply deploying an AI-powered solution is not enough. To truly unlock the power of real-world data (RWD), GenAI must go beyond checking a box or riding the latest buzzword wave. It should provide a guided, intuitive […]
Impact of the New Administration on Vaccine Policy and Access
Manufacturers should be prepared for a period of uncertainty and potential disruption in vaccine policy. The recent overhaul of the CDC’s Advisory Committee on Immunization Practices (ACIP) signals a shift that could affect vaccine recommendations, public trust, and payer coverage decisions. After Robert F. Kennedy Jr. was sworn in as the new secretary of the […]
Push for Change in 340B Drug Pricing Program
As the 340B Drug Pricing Program continues to grow in size and importance, its operations are being scrutinized more than ever. Pharma manufacturers, who have long noted issues with this program, have made various attempts at reform. Their latest strategy — which would move away from up-front discounts to a rebate model — is currently […]
Selling the Script: The Introduction of Private Equity in Retail Pharmacy
Over the past decade, health systems have seen a rapid influx of private equity, with a six-fold increase in acquisitions totaling $10 trillion. As private equity firms continue to explore new methods of investment in health care, the recent announcement that Walgreens Boots Alliance will be acquired by Sycamore Partners seems to be a natural […]
Asembia Trends: IRA Operationalization and the Future of Specialty Therapies
At the end of April, more than 8,000 attendees visited Las Vegas for the Asembia Specialty Pharmacy Summit, otherwise known as AXS25. If you missed the conference, here’s an overview of some of the key areas covered this year: Keeping an Eye on Government Policies AXS25 featured quite a few presentations on the impact of the […]
What to Watch in Second Round of Medicare Drug Price Negotiations
Established by the Inflation Reduction Act in August 2022, the Medicare Drug Price Negotiation Program is still in its infancy, but is expected to impact a wide swath of stakeholders in the U.S. healthcare system. Last year, CMS negotiated prices for the first round of drugs, and in January, the agency revealed its second list […]
GLP-1s and the Evolving Sleep Apnea Landscape
Obstructive sleep apnea (OSA) is a prevalent yet underdiagnosed condition affecting millions worldwide. People with OSA are subject to sudden drops in blood oxygenation levels that can lead to severe cardiovascular, metabolic, and cognitive consequences if the condition remains untreated. Traditionally, OSA has been managed through personal appliances that apply continuous positive airway pressure (CPAP). […]
Payers Prepare for 2025 Medicare Part D Changes
As of 2024, more than 54 million Medicare beneficiaries had prescription drug coverage through Medicare Part D. Of that total, 31 million had Part D coverage alongside a Medicare Advantage plan, and about 23 million had a Part D prescription drug plan. As a result of the Inflation Reduction Act (IRA), significant changes to the […]
What’s Ahead for Market Access in 2025?
As the pharma industry continues to adjust to the provisions of the Inflation Reduction Act (IRA), the country will soon be ushering in a new presidential administration—leaving the future of the IRA in question. Despite ongoing regulatory uncertainty, manufacturers will still be focused on the same concerns: drug development, pipeline performance and ensuring patient access […]
Accessing Weight-Loss GLP-1s: The Role of Compounding Pharmacies
Initially developed to manage type 2 diabetes, glucagon-like peptide-1 (GLP-1) agonist medications have become exceptionally popular for weight loss. High-profile celebrity endorsements and widespread media coverage has led to an overwhelming spike in demand. By any estimation, the American market for weight-loss GLP-1s is enormous. According to a Kaiser Family Foundation analysis, more than 40% […]